Характеристика, механізми дії і місце веноактивних препаратів у лікуванні хронічних захворювань вен нижніх кінцівок за даними рекомендацій 2018 року

V. A. Chernyak, K. K. Karpenko

Анотація


Хронічні захворювання вен нижніх кінцівок, зокрема варикозна і посттромботична хвороба — актуальна соціально-медична проблема, оскільки уражують майже 18 аселения України. Аналіз структури і рівня первинної і накопиченої інвалідності внаслідок хронічних захворювань вен нижніх кінцівок в Україні за період з 2013 до 2017 р., проведений Українським державним НДІ медико-соціальних проблем інвалідності МОЗ України, виявив несприятливі тенденції (Основні показники інвалідності та діяльності медико-соціальних експертних комісій України за 2017 рік: Аналітико-інформаційний довідник / За ред С. І. Черняка. - Дніпро: Акцент ПП, 2018. — 177 с.).

Так, в структурі захворювань периферичних судин дорослого населення частка хронічних захворювань вен нижніх кінцівок збільшилася в 1,3 разу. Основною причиною первинної інвалідності залишається посттромботична хвороба (71,4 %).  За згаданий період частота тяжкої інвалідності зросла в 1,2 разу, а первинної інвалідизації осіб молодого віку внаслідок варикозної хвороби — в 1,9 разу, що свідчить про низький рівень надання медичної допомоги населенню. Причинами цього є не лише низький рівень звернень пацієнтів до лікарів на ранніх стадіях розвитку патології, але і відсутність адекватної медикаментозної профілактики захворювань вен нижніх кінцівок. У зв'язку з цим роль венотоніків досить висока.

Наводимо результати вивчення проблеми хронічних захворювань вен нижніх кінцівок провідних флебологів під егідою Європейського венозного форуму, Міжнародної спілки ангіологів, Міжнародної спілки флебологів, Освітнього і дослідницького центру серцево-судинних захворювань (Велика Британія) у скороченому варіанті.


Повний текст:

PDF (Русский)

Посилання


Ramelet AA, Kern P, Perrin M. Varicose veins and telangiectasias. Paris: Elsevier, 2004.

Ramelet AA, Boisseau MR, Allegra C et al. Venoactive drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc. 2005;33:309-319.

Nicolaides AN, Allegra C, Bergan J et al. Management of chronic venousdisorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008;27:1-59.

Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2005;111:2398-23409.

Bergan JJ, SchmidSchonbein GW, Smith PD et al. Chronic venous disease. N Engl J Med. 2006;355:488-498.

Atta HM. Varicose veins: role of mechanotransduction ofvenous hypertension. Int J Vasc Med. 2012;2012:538-627.

Ibegbuna V, Nicolaides AN, Sowade O et al. Venous elasticity after treatment with Daflon 500 mg. Angiology. 1997;48:45-49.

Gargouil YM, Perdrix L, Chapelain B, Gaborieau R. Effects of Daflon 500 mg on bovine vessels contractility. Int Angiol. 1989;8 (suppl. 4):19S-22S.

Tsouderos Y. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg. Z Kardiol. 1991;80 (suppl. 7):95-101.

Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology. 2000;51:197-205.

Guillaume M, Padioleau F. Veinotonic effect, vascularprotection, antiinflammatory and free radical scavenging properties of horse chestnut extract. Arzneimittel-forschung. 1994;44:25-35.

Bouskela E, Cyrino FZ, Marcelon G. Effects of Ruscusextract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. J Cardiovasc Pharmacol. 1993;22:221-224.

Androulakis G, Panoysis PA. Plethysmographic confirmation of the beneficial effect of calcium dobesilate inprimary varicose veins. Angiology. 1989;40:1-4.

Araujo D, Viana F, Osswald W. Diosmin therapy altersthe in vitro metabolism of noradrenaline by the varicosehuman saphenous vein. Pharmacol Res. 1991;24:253-256.

Araujo D, Gulati O, Osswald W. Effects of two venotropic drugs on inactivation and O-methylation of catecholamines in an isolated canine vein. Arch Int Pharmacodyn Ther. 1985;277:192-202.

Juteau N, Bakri F, Pomies JP et al. The human saphenous vein in pharmacology: effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine induced contraction. Int Angiol. 1995;14 (3 Suppl 1):8-13.

Rubanyi G, Marcelon G, Vanhoutte PM. Effect of temperature on the responsiveness of cutaneous veinsto the extract of Ruscus aculeatus. Gen Pharmacol. 1984;15:431-434.

Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms

for the venular constriction elicited by Ruscus extract on hamster cheek pouch. J Cardiovasc Pharmacol. 1994;24:165-170.

Raffetto JD, Khalil RA. Ca (2+)-dependent contractionby the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins. J Vasc Surg. 2011;54:489-496.

Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem. 2001;8:135-153.

Benavente-Garcia O, Castillo J. Update on uses andproperties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem. 2008;56:6185-6205.

Garcia-Lafuente A, Guillamon E, Villares A et al. Flavonoids as anti-inflammatory agents: implications in cancer and cardiovascular disease. Inflamm Res. 2009;58:537-552.

Wu CH, Wu CF, Huang HW et al. Naturally occurring flavonoids attenuate high glucose-induced expression of proinflammatory cytokines in human monocytic THP-1 cells. Mol Nutr Food Res. 2009;53:984-995.

Akhlaghi M, Bandy B. Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2009;46:309-317.

Shukla VK, Sethi AK, Garg SK et al. Effect of venoruton on hypoxic stress-induced neurotoxicity in mice and oxygen free radical generation by human neutrophils. Arch Int Pharmacodyn Ther. 1989;299:127-133.

Cypriani B, Limasset B, Carrie ML et al. Antioxidant activity of micronized diosmin on oxygen species from stimulated human neutrophils. Biochem Pharmacol. 1993;45:1531-1535.

Jean T, Bodinier MC. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology. 1994;45 (6 Pt 2):554-559.

Blasig IE, Loewe H, Ebert B. Effect of troxerutin and methionine on spin trapping of free oxyradicals. Biomed Biochim Acta. 1988;47. P. S252-255.

Matsuda H, Li Y, Murakami T et al. Effects of escins Ia, Ib, IIa, and IIb from horse chestnut, the seeds of Aesculus hippocastanum L., on acute inflammation in animals. Biol Pharm Bull. 1997;20:1092-1095.

Maffei Facino R, Carini M, Aldini G et al. Free radicals scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung. 1994;44:592-601.

Maffei Facino R, Carini M, Aldini G et al. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med. 1996;62:495-502.

Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med. 1999;27:704-724.

Cho KJ, Yun CH, Packer L, Chung AS. Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann NY Acad Sci. 2001;928:141-156.

Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002;40:158-168.

Iravani S, Zolfaghari B. Pharmaceutical and nutraceutical effects of Pinus pinaster bark extract. Res Pharm Sci 2011. 6:1-11.

Brunet J, Farine JC, Garay RP, Hannaert P. In vitro antioxidant properties of calcium dobesilate. Fundam Clin Pharmacol 1998. 12:205-212.

Szabo ME, Haines D, Garay E et al. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol. 2001;428:277-286.

Alda O, Valero MS, Pereboom D et al. In vitro effect of calcium dobesilate on oxidative/inflammatory stress in human varicose veins. Phlebology. 2011;26:332-337.

Sen CK, Bagchi D. Regulation of inducible adhesion molecule expression in human endothelial cells by grape seed proanthocyanidin extract. Mol Cell Biochem. 2001;216:1-7.

Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial activation response to oral micronized flavonoid therapy in patients with chronic venous disease — a prospective study. Eur J Vasc Endovasc Surg. 1999;17:313-318.

Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg. 2000;31:456-461.

Kauss T, Moynet D, Rambert J et al. Rutoside decreases human macrophage-derived inflammatory mediators and improves clinical signs in adjuvant-induced arthritis. Arthritis Res Ther. 2008;10:R19.

Bito T, Roy S, Sen CK, Packer L. Pine bark extract pycnogenol downregulates IFN-gamma-induced adhesion of T cells to human keratinocytes by inhibiting inducible ICAM-1 expression. Free Radic Biol Med. 2000;28:219-227.

Bergan JJ, Pascarella L, Schmid-Schonbein GW. Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension. J Vasc Surg. 2008;47:183-192.

Tinsley JH, Wu MH, Ma W et al. Activated neutrophils induce hyperpermeability and phosphorylation of adherens junction proteins in coronary venular endothelial cells. J Biol Chem. 1999;274:24930-24934.

He P, Wang J, Zeng M. Leukocyte adhesion and mi crovessel permeability. Am J Physiol Heart Circ Physiol. 2000;278:H1686-1694.

DiStasi MR, Ley K. Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability. Trends Immunol. 2009;30:547-556.

Curry FR, Noll T. Spotlight on microvascular permeability. Cardiovasc Res. 2010;87:195-197.

He P. Leucocyte/endothelium interactions and microvessel permeability: coupled or uncoupled?. Cardiovasc Res. 2010;87:281-290.

Godfraind T. Effect of a flavonoid preparation (S 5682) on experimental capillary permeability increase in rat paw and rabbit skin. Int Angiol. 1988;7 (2):17-19.

Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in diabetic hamsters. Int J Microcirc Clin Exp. 1995;15:293-300.

Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents andon ischemia/reperfusion in the hamster cheek pouch. Angiology. 1997;48:391-399.

Blumberg S, Clough G, Michel C. Effects of hydroxyethyl rutosides upon the permeability of single capillaries in the frog mesentery. Br J Pharmacol. 1989;96:913-919.

Kendall S, Towart R, Michel CC. Effects of hydroxyeth ylrutosides on the permeability of microvessels in the frog mesentery. Br J Pharmacol. 1993;110:199-206.

Gabor M. The effect of O-(beta-hydroxyethyl)-rutosides (HR) on the skin capillary resistance of rats. Arzneimittelforschung. 1981;31:442-445.

Bisler H, Pfeifer R, Kluken N, Pauschinger P. +AFs-Effects of horse-chestnut seed extract on transcapillary filtration in chronic venous insufficiency+AF0. Dtsch Med Wochenschr. 1986;111:1321-1329.

Bouskela E, Cyrino FZ, Marcelon G. Inhibitory effect of the Ruscus extract and of the flavonoid hesperidine methylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch. J Cardiovasc Pharmacol. 1993;22:225-230.

Bouskela E, Cyrino FZ, Marcelon G. Possible mechanisms for the inhibitory effect of Ruscus extract on increased microvascular permeability induced by histamine in hamster cheek pouch. J Cardiovasc Pharmacol. 1994;24:281-285.

Svensjo E, Bouskela E, Cyrino FZ, Bougaret S. Antipermeability effects of Cyclo 3 Fort in hamsters with moder ate diabetes. Clin Hemorheol Microcirc. 1997;17:385-388.

Brunet J, Farine JC, Garay RP, Hannaert P. Angioprotective action of calcium dobesilate against reactive oxygen species-induced capillary permeability in the rat. Eur J Pharmacol. 1998;358:213-220.

Hannaert P, Brunet J, Farine JC, Garay RP. Antioxidant-angioprotective actions of calcium dobesilate in diabetic rats. Int J Angiol. 1999;8:2-4.

Bates DO, Curry FE. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol. 1996;271 (6 Pt 2):H2520-2528.

Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87:262-271.

Shoab SS, Scurr JH, Coleridge-Smith PD. Increased plasma vascular endothelial growth factor among patients with chronic venous disease. J Vasc Surg. 1998;28:535-540.

Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction-a pilot study. Eur J Vasc Endovasc Surg. 1999;18:334-338.

Howlader MH, Coleridge Smith PD. Relationship of plasma vascular endothelial growth factor to CEAP clinical stage and symptoms in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 2004;27:89-93.

Coleridge Smith PD. Deleterious effects of white cells in the course of skin damage in CVI. Int Angiol. 2002;21 (2 (suppl. 1)):S26-32.

Chen WY, Rogers AA. Recent insights into the causes of chronic leg ulceration in venous diseases and implica tions on other types of chronic wounds. Wound Repair Regen. 2007;15:434-449.

Peschen M, Grenz H, Grothe C, Schopf E, Vanscheidt W. Patterns of epidermal growth factor receptor, basic fibroblast growth factor and transforming growth factor-beta3 expression in skin with chronic venous insufficiency. Eur J Dermatol. 1998;8:334-338.

Peschen M, Lahaye T, Hennig B et al. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated inprogressing stages of chronic venous insufficiency. Acta Derm Venereol. 1999;79:27-32.

Pappas PJ, You R, Rameshwar P et al. Dermal tissue fibrosis in patients with chronic venous insufficiency is associated with increased transforming growth factor-beta1 gene expression and protein production. J Vasc Surg. 1999;30:1129-1145.

James TJ, Hughes MA, Cherry GW, Taylor RP. Evidence of oxidative stress in chronic venous ulcers. Wound Repair Regen. 2003;11:172-176.

Wlaschek M, Scharffetter-Kochanek K. Oxidative stress in chronic venous leg ulcers. Wound Repair Regen. 2005;13:452-461.

Clark RA. Oxidative stress and «senescent» fibroblasts in non-healing wounds as potential therapeutic targets. J Invest Dermatol. 2008;128:2361-2364.

Wall IB, Moseley R, Baird DM et al. Fibroblast dysfunction is a key factor in the non-healing of chronic venous leg ulcers. J Invest Dermatol. 2008;128:2526-2540.

Phillips MN, Jones GT, van Rij AM, Zhang M. Micro-venous valves in the superficial veins of the human lower limb. Clin Anat. 2004;17:55-60.

Caggiati A, Phillips M, Lametschwandtner A, Allegra C. Valves in small veins and venules. Eur J Vasc Endovasc Surg. 2006;32:447-452.

Vincent JR, Jones GT, Hill GB, van Rij AM. Failure of microvenous valves in small superficial veins is a key to the skin changes of venous insufficiency. J Vasc Surg. 2011;54 (suppl. 6):62S-69S.

Kahn SR, M’Lan CE, Lamping. et al. Relationship between clinical classification of chronic venous disease and patient-reported quality of life: results from an international cohort study. J Vasc Surg. 2004;39:823-828.

Langer RD, Ho E, Denenberg JO et al. Relationships between symptoms and venous disease: the San Diego population study. Arch Intern Med. 2005;165:1420-1424.

Saarinen J, Suominen V, Heikkinen M et al. The profile of leg symptoms, clinical disability and reflux in legs with previously operated varicose disease. Scand J Surg. 2005;94:51-55.

Chiesa R, Marone EM, Limoni C et al. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46:322-330.

Guex JJ, Enrici E, Boussetta S et al. Correlations between ankle circumference, symptoms, and quality of life demonstrate the clinical relevance of minimal leg swelling reduction: results of a study in 1,036 Argentinean patients. Dermatol Surg. 2008;34:1666-1675.

Bradbury A, Evans CJ, Allan P et al. The relationship between lower limb symptoms and superficial and deep venous reflux on duplex ultrasonography: The Edinburgh Vein Study. J Vasc Surg. 2000;32:921-931.

Bradbury A, Evans C, Allan P et al. What are the symptoms of varicose veins? Edinburgh vein study cross sectional population survey. Br Med J. 1999;318:353-356.

Howlader MH, Smith PD. Symptoms of chronic venous disease and association with systemic inflammatory markers. J Vasc Surg. 2003;38:950-954.

Shami SK, Shields DA, Farrah J et al. Peripheral nerve function in chronic venous insufficiency. Eur J Vasc Surg. 1993;7:195-200.

Padberg FT Jr., Maniker AH, Carmel G et al. Sensory impairment: a feature of chronic venous insufficiency. J Vasc Surg. 1999;30:836-842.

Reinhardt F, Wetzel T, Vetten S et al. Peripheral neuropathy in chronic venous insufficiency. Muscle Nerve 2000. 23:883-887.

Kroger K, Ose C, Rudofsky G et al. Symptoms in individuals with small cutaneous veins. Vasc Med. 2002;7:13-17.

Ruckley CV, Evans CJ, Allan PL et al. Telangiectasia in the Edinburgh Vein Study: epidemiology and association with trunk varices and symptoms. Eur J Vasc Endovasc Surg. 2008;36:719-724.

Andreozzi GM, Signorelli S, Di Pino. et al. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48:277-285.

Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31:105-15.

Danziger N. Pathophysiology of pain in venous disease. J Mal Vasc. 2007;32:1-7.

Boisseau MR. Leukocyte involvement in the signs and symptoms of chronic venous disease. Perspectives for therapy. Clin Hemorheol Microcirc. 2007;37:277-290.

Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. Int J Angiol. 2010;19:e73-77.

Bull RH, Gane JN, Evans JE et al. Abnormal lymph drainage in patients with chronic venous leg ulcers. J Am Acad Dermatol. 1993;28:585-590.

Mortimer PS. Evaluation of lymphatic function: abnormal lymph drainage in venous disease. Int Angiol. 1995;14 (3 Suppl. 1):S32-35.

Mortimer PS. Implications of the lymphatic system in CVI-associated edema. Angiology. 2000;51:3-7.

Suzuki M, Unno N, Yamamoto N et al. Impaired lymphatic function recovered after great saphenous vein stripping in patients with varicose vein: venodynamic and lymphodynamic results. J Vasc Surg. 2009;50:1085-1091.

Tanaka H, Zaima N, Sasaki T et al. Loss of lymphatic vessels and regional lipid accumulation is associated with great saphenous vein incompetence. J Vasc Surg. 2012;55:1440-1448.

Casley-Smith JR. Modern treatment of lymphoedema. II. The benzopyrones. Australas J Dermatol. 1992;33:69-74.

Casley-Smith JR, Morgan RG, Piller NB. Treatment of lymphedema of the arms and legs with 5,6-benzo-+AFs-alpha+ AF0-pyrone. N Engl J Med. 1993;329:1158-1163.

Labrid C. A lymphatic function of Daflon 500 mg. Int Angiol. 1995;14 (3 Suppl 1):36-38.

Piller NB. The lymphogogue action of calcium dobesilate on the flow of lymph from the thoracic duct of anesthetized and mobile guinea pigs. Lymphology. 1988;21:124-127.

Le Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp. 1997;17 (suppl. 1):27-33.

Boisseau MR, Taccoen A, Garreau C et al. Fibrinolysis and hemorheology in chronic venous insufficiency: a double blind study of troxerutin efficiency. J Cardiovasc Surg (Torino) 1995. 36:369-374.

Benarroch IS, Brodsky M, Rubinstein A et al. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res. 1985;17:131-138.

Martinez MJ, Bonfill X, Moreno RM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005:CD003229.

Pittler MH, Ernst E. Horse chestnut seed extract forchronic venous insufficiency. Cochrane Database Syst Rev. 2012;11:CD003230.

Schoonees A, Visser J, Musekiwa A, Volmink J. Pycnogenol (R) (extract of French maritime pine bark) for the treatment of chronic disorders ((R)) for the treatment of chronic disorders. Cochrane Database Syst Rev. 2012;4:CD008294.

Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg. 2005;30:198-208.

Jull AB, Arroll B, Parag V, Waters J. Pentoxifylline for treating venous leg ulcers. Cochrane Database Syst Rev. 2012;12. CD001733.

Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41:117-125.

Guyatt G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006;129:174-181.

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J. 2008;336:924-926.

Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assessment and quality of life improvement with micronized flavonoids. Angiology. 2002;53:245-256.

Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol. 2012;31:310-315.

Allaert FA, Hugue C, Cazaubon M et al. Correlation between improvement in functional signs and plethysmographic parameters during venoactive treatment (Cyclo 3 Fort). Int Angiol. 2011;30:272-277.

Rabe E, Jaeger KA, Bulitta M, Pannier F. Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial. Phlebology. 2011;26:162-168.

Labs KH, Degisher S, Gamba G, Jager KA. Effectiveness and safety of calcium dobesilate in treating chronic venous insufficiency: randomized double blind placebo-controlled trial. Phlebology. 2004;19:123-130.

Flota-Cervera F, Flota-Ruiz C, Trevino C, Berber A. Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease. Angiology. 2008;59:352-356.

Martinez-Zapata MJ, Moreno RM, Gich I et al. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilatewith placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg. 2008;35:358-365.

Rabe E, Stucker M, Esperester A et al. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg. 2011;41:540-547.

Kalus U, Koscielny J, Grigorov A et al. Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study. Drugs R D. 2004;5:63-71.

Kulessa W, Becker EW, Berg PA. Recurrent agranulocytosis after taking calcium dobesilate. Dtsch Med Wochenschr. 1992;117:372-374.

Cladera Serra A, Blasco Mascaro I, Oliva Berini E, Ramos Diaz F. Agranulocytosis induced by calcium dobesilate. Med Clin (Barc). 1995;105:558-559.

Garcia Benayas E, Garcia Diaz B, Perez G. Calcium dobesilate-induced agranulocytosis. Pharm World Sci. 1997;19:251-252.

Ibanez L, Ballarin E, Vidal X, Laporte JR. Agranulocytosis associated with calcium dobesilate clinical course and risk estimation with the case-control and the case-population approaches. Eur. J Clin Pharmacol. 2000;56:763-767.

Zapater P, Horga JF, Garcia A. Risk of drug-induced agranulocytosis: the case of calcium dobesilate. Eur. J Clin Pharmacol. 2003;58:767-772.

Allain H, Ramelet AA, Polard E, Bentue-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf. 2004;27:649-660.

Ibanez L, Vidal X, Ballarin E, Laporte JR. Population based drug-induced agranulocytosis. Arch Intern Med. 2005;165:869-874.

Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology. 2005;41:925-935.

Loprinzi CL, Sloan J, Kugler J. Coumarin-induced hepatotoxicity. J Clin Oncol. 1997;15:3167-318.

Danielsson G, Jungbeck C, Peterson K, Norgren L. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg. 2002;23:73-76.

Raju S, Hollis K, Neglen P. Use of compression stockings in chronic venous disease: patient compliance and efficacy. Ann Vasc Surg. 2007;21:790-795.

Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4:CD003229.

Boyle P, Diehm C, Robertson C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int Angiol. 2003;22:250-262.

Kakkos SK, Allaert FA. Efficacy of Ruscus extract, HMC and vitamin C, constituents of Cyclo 3 fort®, on improving individual venous symptoms and edema: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2017;36:93-106.

Kakkos S, Nicolaides AN. Efficacy of purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;Jan 31.

Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse chronique des membres inférieurs. J Int Med. 1987;Suppl. 99:36-39.

Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-380.

Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34:428-436.

Biland L, Blattler P, Scheibler P et al. Zur Therapie sogenannt venoser Beinbeschwerden. (Kontrollierte Doppelblind-Studie zur Untersuchung der therapeutischen Wirksamkeit von Daflon). Vasa 1982. 11:53-58.

Chassignolle J-F, Amiel M, Lanfranchi G, Barbe R. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse fonctionnelle. J Int Med. 1987;suppl. 99:32-35.

Tsouderos Y. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg. Int Angiol. 1989;8 (suppl. 4):53-59.

Belczak SQ, Sincos IR, Campos W et al. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel design trial. Phlebology. 2014;29:454-460.

Parrado F, Buzzi A. A study of the efficacy and tolerability of a preparation containing Ruscus aculeatus in the treatment of chronic venous insufficiency of the lower limbs. Clin Drug Investig. 1999;18:255-261.

Questel R, Walrant P. Bilan de l’essai randomisé Veinobiase contre placebo dans l’unsuffisance veineuse: observation de la microcirculation per capillarographie conjonctivale. Gazette Medicale de France. 1983;90:508-514.

Elbaz C, Nebot F, Reinharez D. Insuffisance veineuse des membres inférieurs étude controleé de l’action du Cyclo 3. Phlébologie 1976. 29:77-84.

Altenkamp H. Efficacy of antivaricotic drugs can be measured objectively. Phlebologie in der praxis. 1987;2:9-20.

Le Devehat C, Lemoine A, Roux E et al. Aspects clinique et hémodynamique de Cyclo 3 dans l’insuffisance veineuse. Angéiologie 1984. 3:119-122.

Sentou Y, Bernard-Fernier MF, Demarez JP et al. Symptomatologie et pléthysmographie: Parallélisme des résultants obtenus lors d’un traitement par Cyclo 3 de patientes porteuses d’une insuffisance neineuse chronique (étude en double insu contre placebo). Gazette Medicale de France. 1985;92:73-77.

Braun R, Hirche H, van Laak H-H. Die therapie der venösen insuffizienz: eine doppelblind-studie mit Phlebodril®. ZFA 1985. 61:309-319.

Vanscheidt W, Jost V, Wolna P et al. Efficacy and safety of a Butcher’s broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung. 2002;52:243-250.

Rieger H. Efficacy of a combination drug in patients with chronic venous insufficiency under orthostatic conditions. Phlebology. 1988;3:127-130.

Rudofsky G, Diehm C, Gruβ JD et al. Chronic venous insufficiency. Treatment with Ruscus extract and trimethylhesperidin chalcone. MMW Munch Med Wochenschr. 1990;132:205-210.

Aziz Z1., Tang WL, Chong NJ, Tho LY. A systematic review of the efficacy and tolerability of hydroxyethyl rutosides for improvement of the signs and symptoms of chronic venous insufficiency. J Clin Pharm Ther. 2015;40:177-185.

Belcaro G, Rulo A, Candiani C. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements. Vasa. 1989;18:146-151.

Cloarec M, Clement R, Griton P. A double-blind clinical trial of hydroxyethylurosides in the treatment of the symptoms and signs of chronic venous insufficiency. Phlebology. 1996;11:76-82.

Pedersen FM1, Hamberg O, Sørensen MD, Neland K. Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs. Ugeskr Laeger. 1992;154:2561-2563.

Welsh W, Moriau M, van Gysel JP. A double blind placebo-controlled trial of o- (beta-hydroxyethyl)-rutosides in patients with chronic venous insufficiency. Basel: Novartis; 1985.

Petruzzellis V, Troccoli T, Candiani C et al. Oxerutins (Venoruton): efficacy in chronic venous insufficiency-a double-blind, randomized, controlled study. Angiology. 2002;53:257-63.

Stegmann WAE, Deichmann B, Hubner K. Therapeutic effect of hydroxyethylrutosides (HR) in venous ulcer treatment. A controlled multicentre trial. Phlebology. 1986;1:617-620.

Incandela L, Belcaro G, Renton S, DeSanctis MT, Cesarone MR, Bavera P et al. HR (Paroven, Venoruton; 0- (beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. J Cardiovasc Pharmacol Ther. 2002;7 (suppl. 1):S7-S10.

Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:834-40.

Cloarec M. Study on the effect of a new vasoprotective Venostasin administered over a period of 2 months in chronic venous insufficiency of the lower limb (data from 1992). Data on file (quoted by Pittler and Ernst Ref 110 above).

Friederich HC, Vogelsberg H, Neiss A. [Evaluation of internally effective venous drugs]. Z Hautkr. 1978;53:369-374.

Lohr E, Garanin G, Jesau P, Fischer H. [Anti-edemic treatment in chronic venous nsufficiency with tendency to formation of oedema]. MMW Munch Med Wochenschr 1986. 128:579-581.

Morales Paris CA, Barros Soares RM. Efficacy and safety on use of dried horse chestnut extract in the treatment of chronic venous insufficiency of the limbs. Revista Brasileira de Medicina 1993. 50:1563-1565.

Neiss A, Böhm C. [Demonstration of the effectiveness of horse chestnut seed extract in the varicose syndrome complex]. MMW Munch Med Wochenschr. 1976;118:213-216.

Rudofsky G, Neiss A, Otto K, Seibel K. [Oedema-protective effect and clinical efficacy of horse chestnut seed extract in a double blind study]. Phlebologie und Proktologie. 1986;15:47-54.

Steiner M. Investigation into the oedema reducingand oedema protective effects of horse chestnut seed extract [Untersuchungen zur ödemvermindernden und ödemprotektiven Wirkung von Roßkastaniensamenextrakt]. Phlebologie und Proktologie. 1990;19:239-242.

Steiner M, Hillemanns HG. [Tests for anti-oedema action of a venous therapy]. MMW Munch Med Wochenschr. 1986;128:551-552.

Diehm C, Schmidt C. Venostasin retard gegen Plazebo und Kompression bei Patienten mit CVI II/IIIA. Final Study Report. Munich: Klinge Pharma GmbH; 2000.

Diehm C, Vollbrecht D, Amendt K, Comberg HU. Medical edema protection — Clinical benefit in patients with chronic deep vein incompetence. Vasa. 1992;21:188-192.

Diehm C, Trampisch HJ, Lange S, Schmidt C. Comparison of leg compression stocking and oral horsechestnut seed extract therapy in patients with chronic venous insufficiency. Lancet. 1996;347:292-294.

Chiapponi A, Laffaire E, Roque M. Calcium dobesilate for chronic venous insufficiency: a systematic review. Angiology. 2004;55:147-154.

Hachen HJ, Lorenz P. Double-blind clinical and ple-thysmographic study of calcium dobesilate in patients with peripheral microvascular disorders. Angiology. 1982;33:480-488.

Widmer L, Biland L, Barras JP. Doxium 500 in chronic venous insufficiency: a double-blind placebo-controlled multicentre study. Int Angiol. 1990;9:105-110.

Marinello 2002. Ensayo clinic multicentric, doble ciego, aleatorizado, controlado con placebo sobrela effecta del dobesilato de calico en el tratamiento de la hypertension venosa en patients afectos de insuficienta venosa cronica de extremidades inferiors. ESCLIN-004/99 (Quoted by Ciapponi 2004 in ref 180 above).

Casley-Smith JR. A double-blind trial of calcium dobesilate in chronic venous insufficiency. Angiology. 1988;39:853-857.

Flora LF. Estudio clinic prospective aleatorizado doble ciego, con control placebo, para evaluar la eficacia en la resolucion del edema de origin linfatico, del dobesilato de calico en pacientes con enfermedad varicose. No de Proyec. Knoll-mex-02-99. No de Proyec. 003/MEX/99, 1999

DX-1994. Efficacy and safety of Doxium 500 in chronic venous insufficiency. A double-blind placebo-controlled multicentre study. The clinical study report. Study number DX-1994/2: 1-114. 2000.

Rabe E, Ballarini S, Lehr L. A randomized, doubleblind, placebo-contrlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology. 2016;31:264-274.

Hammerschmidt DE, Kotasek D, McCarthy T, Huh PW, Freyburger G, Vercellotti GM. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med. 1988;112:254-263.

Cocceri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013;8:49-65.

Wu B, Lu J, Yang M, Xu T. Sulodexide for treating venous leg ulcers. Cochrane Database Syst Rev. 2016;6:CD010694

Cocceri S, Bignamini AA. Pharmacological adjuncts for chronic venous ulcer healing. Phlebology. 2016;31:366-367.

Zuccarelli F, Taccoen A, Coget JM. Treatment of venous ulcers with troxerutin: a randomized double-blind, controlled study. Int Angiol. 1987;15:53-58.

Nicolaides AN, Kakkos S, Eklof B et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Chapter 8. Venoactive Drugs. Int Angiol. 2014;33:126-139.

Perrin M, Eklof B, van Rij A, Labropoulos N, Vasquez M, Nicolaides A et al. Venous symptoms: the SYMvein Consensus statement developed under the auspices of the European Venous Forum. Int Angiol. 2016;35:374-398.

Lee BB, Nicolaides AN, Myers K et al. Venous hemodynamic changes in lower limb venous disease: the UIP consensus according to scientific evidence. Int Angiol. 2016;35:236-352.

De Souza MGC, Cyrino FZ, Mayal MR et al. Beneficial effects of the micronized purified flavonoid fraction (MPFF, Daflon 500 mg) on microvascular damage elicited by sclerotherapy. Phlebology. 2016;31:50-56.

Bogachev VY, Golovanova OV, Kuznetsov AN, Sheokyan AO; the DECISION investigators group. Can micronized purified flavonoid fraction (MPFF) improve outcomes of lower extremity varicose vein endovenous treatment? First results from DECISION study. Phlebolymphology. 2013;20:181-187.

Bogachev VY, Boldin BV, Lobanov VN. Benefits of micronized purified flavonoid fraction as adjuvant therapy on the inflammatory response after sclerotherapy. Int Angiol. 2018;37:71-78.

Pitsch F. Benefit of Daflon 500 mg in combination with sclerotherapy of telangiectasias of the lower limbs: results from the SYNERGY and SATISFY surveys. Phlebolymphology. 2011;19:182-187.

Saveljev VS, Pokrovsky AV, Kirienko AI et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicentre controlled trial DEANCE). Phlebolymphology. 2008;15:45-51.

Verenkova L, Kalac J, Jedlicka V, Wechsler J. Analysis of the various procedures used in great saphenous vein surgery in the Chech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology. 2006;13:193-199.

Mazzaccaro D, Muzzarelli L, Modafferi A et al. Use of venoactive drugs after surgery for varicose veins: a preliminary study. Int Angiol. 2018;37:79-84.

Raffetto JD, Eberhardt RT, Dean SM et al. Pharmacologic treatment to improve venous leg ulcer healing. J Vasc Surg Ven Lym Dis. 2016;4:371-37 4.

Marcelon G, Pouget G, Tisné-Versailles J. Effect of Ruscus on the adenoreceptors of the canine lymphatic thoracic duct. Phlebology. 1988;3 (S1):109-112.

Le Devehat F. The effect of Cyclo 3 Fort treatment on hemorheological disturbances during a provoked venous stasis in patients with chronic venous insufficiency. Clin Hemorheol. 1994;14 (S1):53-63.

Guyatt GH, Cook DJ, Sackett DL et al. Grades of recommendation for antithrombotic agents. Chest. 1998;114 (suppl. 5):441S-444S.

Guyatt G, Gutterman D, Baumann MH et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American college of chest physicians task force. Chest. 2006;129:174-181.




© Хірургія України, 2019
© ТОВ «ВІТ-А-ПОЛ», 2019